Study guide
9.3 Neonatal Hypoglycemia, Electrolyte Derangements & Hyperbilirubinemia
Neonatal Pediatric Transport C-NPT
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The C-NPT Exam
About the C-NPT Exam: 2026 Format, Eligibility & Content Outline
2 Chapter 1: Transport Systems, Regulatory Framework & Legal Issues
1.1 Transport System Architecture, Accreditation (CAMTS) & Dispatch Triage 1.2 Regulatory & Legal Mandates: EMTALA, HIPAA, Consent & Documentation 1.3 Medical Direction, Scope of Practice & Ethical Considerations
3 Chapter 2: Safety, Communication, Crew Resource Management & Transport Environment
2.1 Crew Resource Management (CRM), Situational Awareness & Sterile Cockpit 2.2 Aircraft & Ground Ambulance Operations, Landing Zones & Vehicle Dynamics 2.3 Environmental Hazards, Weather Minimums & In-Flight Emergency Procedures 2.4 Communication in Transport: Peer Handoffs, Age-Appropriate Care, Families & Crew Stressors 2.5 Infection Control, PPE, Scene Safety & Disaster/Evacuation Planning
4 Chapter 3: Flight Physiology & Environmental Stressors
3.1 Physical Gas Laws & Transport Implications (Boyle, Dalton, Charles, Henry, Graham) 3.2 Altitude Hypoxia, Barometric Pressure Changes & Dysbarism 3.3 Acceleration Forces (G-forces), Vibration & Acoustic Stress in Transit 3.4 Thermoregulation Physics & Neutral Thermal Environment in Transit
5 Chapter 4: Invasive Procedures & Transport Monitoring
4.1 Advanced Airway Management & Endotracheal Intubation in Transit 4.2 Pleural Decompression (Needle Thoracostomy & Chest Tube Management) 4.3 Vascular Access: Umbilical Lines (UAC/UVC), Intraosseous (IO) & Arterial Lines
6 Chapter 5: Transport Equipment, Respiratory Physiology & Mechanical Ventilation
5.1 Transport Incubators (Isolettes), Thermal Control & Electrical/Gas Power Systems 5.2 Portable Ventilators & Modes (PC, VC, PRVC, High Frequency) 5.3 Gas Cylinder Duration Calculations, Oxygen Delivery & Inhaled Nitric Oxide (iNO) 5.4 Respiratory Physiology: Acid-Base Balance, Oxygenation, Lung Mechanics & Troubleshooting
7 Chapter 6: Transport Pharmacology, Resuscitation, Fluids & Electrolytes
6.1 Vasoactive Infusions & Inotropes (Epinephrine, Dopamine, Dobutamine, Milrinone) 6.2 Sedation, Analgesia & Neuromuscular Blockade in Transport 6.3 Prostaglandin E1 (Alprostadil) & Surfactant Replacement Therapy 6.4 Resuscitation Protocols (NRP, PALS) & Shock Fluid Resuscitation 6.5 Antimicrobial Pharmacology in Neonatal & Pediatric Transport 6.6 Post-Resuscitation Care, Defibrillation & Cardioversion in Transit, ECMO Indications & the Transport-vs-Stay Decision 6.7 Fluid & Electrolyte Therapy Across the Ages: Maintenance, Dehydration, Fluid Overload & Electrolyte Emergencies
8 Chapter 7: Neonatal Respiratory Pathologies & Management
7.1 Respiratory Distress Syndrome (RDS) & Surfactant Deficiency 7.2 Meconium Aspiration Syndrome (MAS) & Persistent Pulmonary Hypertension (PPHN) 7.3 Transient Tachypnea (TTN), Neonatal Pneumothorax & Congenital Diaphragmatic Hernia (CDH) 7.4 Neonatal Upper Airway Anomalies, Aspiration, Pneumonia, Chronic Lung Disease & Respiratory Failure
9 Chapter 8: Neonatal Cardiovascular Critical Care
8.1 Ductal-Dependent Cyanotic Congenital Heart Defects (TGA, TOF, Tricuspid Atresia) 8.2 Ductal-Dependent Systemic Blood Flow Lesions (HLHS, Coarctation, Interrupted Arch) 8.3 Neonatal Arrhythmias, Cardiogenic Shock & Post-Resuscitation Care 8.4 Acyanotic Congenital Heart Lesions, Patent Ductus Arteriosus, Obstructed TAPVR & Neonatal Heart Failure
10 Chapter 9: Neonatal Neurological & Metabolic Crises
9.1 Hypoxic-Ischemic Encephalopathy (HIE) & Passive/Active Therapeutic Hypothermia 9.2 Neonatal Seizures & Intraventricular Hemorrhage (IVH) 9.3 Neonatal Hypoglycemia, Electrolyte Derangements & Hyperbilirubinemia 9.4 Subgaleal Hemorrhage, Neonatal Sepsis & Meningitis, and Perinatal Substance Exposure (NOWS)
11 Chapter 10: Neonatal Surgical Emergencies, Neural Tube Defects & ELBW Care
10.1 Abdominal Wall Defects (Gastroschisis vs. Omphalocele) & TEF/Esophageal Atresia 10.2 Necrotizing Enterocolitis (NEC), Malrotation with Volvulus & Intestinal Obstruction 10.3 Care of the Extremely Low Birth Weight (ELBW) Infant (<1000g) in Transit 10.4 Neural Tube Defects: Myelomeningocele, Encephalocele & Transport of the Newborn With an Open Spinal Defect
12 Chapter 11: Pediatric Respiratory Emergencies
11.1 Acute Upper Airway Obstruction (Croup, Epiglottitis, Bacterial Tracheitis, Foreign Body) 11.2 Lower Airway Crises: Status Asthmaticus & Severe Bronchiolitis 11.3 Pediatric Acute Respiratory Distress Syndrome (PARDS) & Severe Pneumonia
13 Chapter 12: Pediatric Shock & Cardiovascular Crises
12.1 Pathophysiology & Transport Management of Pediatric Septic Shock 12.2 Hypovolemic, Cardiogenic & Anaphylactic Shock in Children 12.3 Pediatric Cardiac Emergencies: SVT, Ventricular Arrhythmias & Myocarditis 12.4 Pediatric Cardiovascular Crises: Palliated Congenital Heart Disease, Pulmonary Hypertensive Crisis, Pericarditis & Tamponade, Hypertensive Emergency & Anterior Mediastinal Mass
14 Chapter 13: Pediatric Neurological Emergencies & Trauma
13.1 Status Epilepticus, Altered Mental Status & Meningitis/Encephalitis 13.2 Pediatric Traumatic Brain Injury (TBI) & Increased Intracranial Pressure (ICP) 13.3 Blunt/Penetrating Trauma, Spinal Motion Restriction & Thermal Burns 13.4 Non-Accidental Trauma, Smoke Inhalation (Carbon Monoxide & Cyanide) & Heat Illness
15 Chapter 14: Pediatric Toxicological, Environmental & Endocrine Emergencies
14.1 Common Pediatric Toxic Ingestions, Poisonings & Antidotes 14.2 Diabetic Ketoacidosis (DKA) & Environmental Emergencies (Submersion, Hypothermia) 14.3 Button Battery & Foreign-Body Ingestions, Bites & Envenomations, and Hazardous-Material Exposures
16 Chapter 15: Pediatric Metabolic & Hematologic Emergencies
15.1 Anemia, Sickle Cell Disease, Coagulopathies & Blood Product Administration 15.2 Oncologic Emergencies, Acute Kidney Injury & Pediatric Electrolyte Crises
9.3 Neonatal Hypoglycemia, Electrolyte Derangements & Hyperbilirubinemia
Key Takeaways Explain This Topic AI
Symptomatic neonatal hypoglycemia (glucose below 40 mg/dL per the AAP) needs immediate treatment with a 10% Dextrose (D10W) mini-bolus of 2 mL/kg (200 mg/kg) over 5 minutes followed by a continuous infusion delivering a Glucose Infusion Rate (GIR) of 4-8 mg/kg/min; peripheral IV lines must never exceed D12.5W.
Acute symptomatic hypocalcemia (ionized calcium <1.0-1.1 mmol/L) presents with neuromuscular excitability, stridor, prolonged QTc intervals, and refractory seizures, treated with 10% Calcium Gluconate (1-2 mL/kg IV over 10-30 minutes under continuous cardiac monitoring for sudden sinus bradycardia).
Life-threatening hyperkalemia (K+ >6.0-6.5 mEq/L with peaked T waves or QRS widening) requires immediate cardiac membrane stabilization with 10% Calcium Gluconate (1-2 mL/kg IV over 5-10 minutes) prior to shifting potassium intracellularly using insulin-dextrose infusions, nebulized albuterol, or sodium bicarbonate.
Severe unconjugated hyperbilirubinemia carries grave neurotoxic risks of Acute Bilirubin Encephalopathy (ABE) and kernicterus, requiring continuous in-transit fiberoptic phototherapy (biliblanket) with secure eye protection and proactive preparation for double-volume exchange transfusion (DVET; 160-180 mL/kg reconstituted whole blood).
Last updated: September 2026
Neonatal Hypoglycemia, Electrolyte Derangements & Hyperbilirubinemia
Metabolic homeostasis in the neonate is uniquely precarious. During the immediate post-birth transition, an infant must shift from continuous transplacental nutrient delivery to autonomous endocrine regulation, gluconeogenesis, and independent electrolyte filtration. Critical illness, asphyxia, prematurity, or maternal metabolic disorders rapidly overwhelm these transitional mechanisms. Failure to swiftly identify and correct neonatal hypoglycemia, severe electrolyte disturbances, and hyperbilirubinemia results in permanent neurodevelopmental disability, cardiac arrest, or death during transport.
Neonatal Hypoglycemia: Thresholds, High-Risk Groups & GIR Calculations
The neonatal brain relies almost exclusively on continuous glucose oxidation for cerebral metabolic energy. Because ketone body production and glycogenolysis are limited in high-risk newborns, sustained or recurrent neuroglycopenia precipitates cerebral edema, parietal-occipital cortical necrosis, and long-term cognitive and visual impairment.
Operational Definitions & Treatment Thresholds
Guidance differs by source and hour of life:
AAP (2011), at-risk late preterm and term infants: A symptomatic infant with glucose below 40 mg/dL receives IV dextrose. For asymptomatic infants, the AAP algorithm uses feeding and rechecks, with IV dextrose if glucose stays below about 25 mg/dL in the first 4 hours or below about 35 mg/dL at 4–24 hours; the pre-feed goal is at least 45 mg/dL.
Pediatric Endocrine Society (2015): Keep glucose above 50 mg/dL in the first 48 hours and above 60 mg/dL after 48 hours (above 70 mg/dL when a persistent hypoglycemia disorder such as hyperinsulinism is suspected).
In transport: A sick infant who is NPO needs IV dextrose. A commonly used steady-state target during stabilization is about 60–100 mg/dL .
High-Risk Neonatal Populations
Hyperinsulinemic States: Infants of Diabetic Mothers (IDM) and Large-for-Gestational-Age (LGA) infants. Chronic maternal hyperglycemia induces fetal pancreatic islet beta-cell hyperplasia and excessive fetal insulin production. At birth, maternal glucose abruptly ceases upon cord clamping, but hyperinsulinemia persists, driving glucose into muscle and fat while shutting down gluconeogenesis.
Inadequate Glycogen & Fat Stores: Premature infants ( < 37 <37 < 37 weeks) and Small-for-Gestational-Age (SGA) / Intrauterine Growth Restriction (IUGR) infants lack late-trimester hepatic glycogen deposition and brown adipose tissue.
Increased Metabolic Utilization: Asphyxiated neonates (HIE), septic infants, hypothermic infants, and those in acute respiratory distress shift to inefficient anaerobic glycolysis (yielding only 2 ATP per glucose molecule compared to 36–38 ATP under aerobic conditions), exhausting glucose stores at an exponential rate.
Emergency Dextrose Therapy & The GIR Formula
Acute Symptomatic Mini-Bolus: Administer 10% Dextrose in Water (D10W) at 2 mL/kg (equivalent to 200 mg/kg 200 \text{ mg/kg} 200 mg/kg or 0.2 g/kg 0.2 \text{ g/kg} 0.2 g/kg ) as a slow intravenous push over 5 minutes .
Critical Safety Mandate: Never administer concentrated dextrose (D25W or D50W) to a neonate. Hypertonic dextrose causes severe rebound hyperinsulinemia, hyperosmolality, and endothelial sloughing.
Continuous Maintenance Infusion: Follow the mini-bolus immediately with a continuous dextrose infusion titrated to a physiological Glucose Infusion Rate (GIR) . GIR ( mg/kg/min ) = % Dextrose × Hourly IV Rate ( mL/hr ) Patient Weight ( kg ) × 6 \text{GIR } (\text{mg/kg/min}) = \frac{\% \text{ Dextrose} \times \text{Hourly IV Rate } (\text{mL/hr})}{\text{Patient Weight } (\text{kg}) \times 6} GIR ( mg/kg/min ) = Patient Weight ( kg ) × 6 % Dextrose × Hourly IV Rate ( mL/hr ) GIR ( mg/kg/min ) = % Dextrose × Daily IV Volume ( mL/kg/day ) 144 \text{GIR } (\text{mg/kg/min}) = \frac{\% \text{ Dextrose} \times \text{Daily IV Volume } (\text{mL/kg/day})}{144} GIR ( mg/kg/min ) = 144 % Dextrose × Daily IV Volume ( mL/kg/day )
Clinical Application: Normal hepatic glucose production in healthy term infants is 4 to 6 mg/kg/min . High-risk infants, IDMs, and SGA neonates often require initial GIRs of 6 to 8 mg/kg/min , titrating upward in increments of 1 to 2 mg/kg/min up to 12 to 15+ mg/kg/min for refractory hyperinsulinism.
Vascular Delivery Limits: The maximum dextrose concentration that can be safely infused through a peripheral intravenous catheter is 12.5% (D12.5W) . Concentrations > 12.5 % >12.5\% > 12.5% (e.g., D15W, D20W) have high osmolarity ( > 900 mOsm/L >900 \text{ mOsm/L} > 900 mOsm/L ) that rapidly induces chemical phlebitis, vascular sclerosis, and full-thickness skin necrosis if extravasated. Central venous access (Umbilical Venous Catheter [UVC] or PICC) is mandatory for concentrations exceeding D12.5W.
- Acute Electrolyte Derangements: Calcium, Sodium & Potassium
- 1. Neonatal Hypocalcemia
Definitions: Ionized calcium ( i C a iCa i C a ) < 1.0 to 1.1 mmol/L < 1.0 \text{ to } 1.1 \text{ mmol/L} < 1.0 to 1.1 mmol/L ( < 4.0 to 4.4 mg/dL < 4.0 \text{ to } 4.4 \text{ mg/dL} < 4.0 to 4.4 mg/dL ) or total serum calcium < 7.0 to 8.0 mg/dL < 7.0 \text{ to } 8.0 \text{ mg/dL} < 7.0 to 8.0 mg/dL in term infants ( < 6.5 to 7.0 mg/dL < 6.5 \text{ to } 7.0 \text{ mg/dL} < 6.5 to 7.0 mg/dL in preterms).
Pathophysiology: Placental calcium transfer ceases at delivery. Early hypocalcemia ( < 72 <72 < 72 hours) occurs in prematurity, asphyxia (calcium deposition in damaged tissues and hyperphosphatemia), and IDM (maternal hypomagnesemia suppresses fetal parathyroid hormone).
Clinical Manifestations: Neuromuscular excitability (jitteriness, high-pitched cry, hyperreflexia), prolonged QTc interval on EKG ( > 0.42 – 0.44 s >0.42\text{--}0.44 \text{ s} > 0.42 – 0.44 s ), stridor/laryngospasm, myocardial dysfunction with hypotension, and seizures refractory to phenobarbital.
Emergency Treatment: 10% Calcium Gluconate at 1 to 2 mL/kg (100 to 200 mg/kg) diluted 1:1 with sterile water or normal saline, infused slowly IV over 10 to 30 minutes .
Transport Mandates: Continuous cardiac rhythm monitoring is mandatory during infusion. Rapid bolusing triggers acute sinus bradycardia, sinus arrest, or fatal ventricular arrhythmias. Stop infusion immediately if heart rate drops. Ensure absolute line patency; extravasation causes severe subcutaneous calcinosis and sloughing. Never administer calcium gluconate through the same line as sodium bicarbonate , as it precipitates into insoluble calcium carbonate chalk.
2. Dysnatremias: Hyponatremia vs. Hypernatremia
Hyponatremia ( N a + < 135 mEq/L Na^+ < 135 \text{ mEq/L} N a + < 135 mEq/L ; Critical < 120 − 125 mEq/L < 120-125 \text{ mEq/L} < 120 − 125 mEq/L ): Caused by excessive free-water administration, SIADH (post-asphyxia or CNS infection), or salt-wasting renal disease. Severe acute hyponatremia causes cerebral edema, encephalopathy, and intractable seizures.
Treatment of Symptomatic Seizures: Administer 3% Hypertonic Saline at 3 to 5 mL/kg IV slowly over 15 to 30 minutes to rapidly elevate serum sodium by 3 to 5 mEq/L, aborting cerebral herniation.
Hypernatremia ( N a + > 145 − 150 mEq/L Na^+ > 145-150 \text{ mEq/L} N a + > 145 − 150 mEq/L ): Caused by severe dehydration, inadequate breast milk intake, or excessive transepidermal evaporative water loss in ELBW infants under radiant warmers. Rapid reduction of hypernatremia leads to water rushing into hyperosmolar brain cells, causing acute brain swelling, herniation, and death. The rate of serum sodium reduction must strictly not exceed 0.5 mEq/L/hr (maximum 10 to 12 mEq/L per 24 hours).
3. Hyperkalemia
Definitions: Serum potassium > 6.0 mEq/L >6.0 \text{ mEq/L} > 6.0 mEq/L in term infants or > 6.5 mEq/L >6.5 \text{ mEq/L} > 6.5 mEq/L in preterm infants. Always rule out pseudohyperkalemia caused by heelstick hemolysis.
- EKG Progression Ladder: Normal EKG ──> Tall, peaked, tented T waves (narrow base)
- ──> Prolongation of PR interval & flattening of P waves
- ──> Widened QRS complex & bundle branch block patterns
- ──> Sine-wave rhythm ──> Ventricular Fibrillation / Asystole
Intervention Step Medication / Therapy Transport Dose & Route Mechanism & Onset
1. Myocardial Stabilization (Immediate) 10% Calcium Gluconate 1 to 2 mL/kg (100–200 mg/kg) IV over 5–10 min Directly antagonizes potassium's cardiotoxicity on cardiac myocytes; stabilizes membrane potential within 1–3 minutes (does NOT lower serum K+)
2. Intracellular Shift: Insulin & Dextrose Regular Insulin + D10W Regular insulin 0.1 unit/kg IV with glucose about 0.5 g/kg (for example, D10W 5 mL/kg), then close glucose checks Activates cell membrane Na+/K+-ATPase, driving K+ into cells within 15–30 minutes
3. Intracellular Shift: Beta-2 Agonist Nebulized Albuterol 0.4 mg/kg (or 2.5 mg nebulized) via ventilator circuit Stimulates beta-2 receptors, activating Na+/K+-ATPase within 15–30 minutes
4. Intracellular Shift: Alkalinization Sodium Bicarbonate 1 to 2 mEq/kg IV slow infusion over 20–30 min Promotes H+/K+ exchange across cell membrane; useful only if concurrent metabolic acidosis is present
5. Potassium Elimination (Definitive) Furosemide (Lasix) 1 mg/kg IV Promotes renal kaliuresis (requires adequate renal perfusion and output)
Severe Neonatal Hyperbilirubinemia & Kernicterus
Hyperbilirubinemia is ubiquitous in neonates due to high red blood cell turnover, immature hepatic uridine diphosphate glucuronosyltransferase (UGT1A1) activity, and increased enterohepatic circulation. When unconjugated (indirect), lipid-soluble bilirubin exceeds the albumin-binding capacity, free unconjugated bilirubin crosses the blood-brain barrier.
Neurotoxicity & Target Nuclei
Free bilirubin deposits selectively in lipid-rich central nervous system structures, specifically the globus pallidus , subthalamic nuclei , hippocampus , oculomotor nuclei , and auditory brainstem nuclei .
Acute Bilirubin Encephalopathy (ABE) Clinical Phases
Phase 1 (Early / Reversible): Mild lethargy, general hypotonia, poor sucking, and a high-pitched cry. Swift intervention can prevent permanent damage.
Phase 2 (Intermediate): Irritability alternating with lethargy, high-pitched screeching cry, hypertonia of extensor muscles manifested as retrocollis (severe involuntary backward arching of the neck) and opisthotonos (severe backward arching of the entire spine), fever, and stupor.
Phase 3 (Advanced / Irreversible): Severe retrocollis/opisthotonos, bicycling or seizure-like movements, apnea, inability to feed, deep coma, and death. Survivors develop chronic kernicterus (choreoathetoid cerebral palsy, sensorineural deafness, upward gaze palsy, and dental enamel dysplasia).
Transport Phototherapy Management
Continuous In-Transit Phototherapy: Severe hyperbilirubinemia approaching exchange levels requires uninterrupted intensive phototherapy. Utilize specialized fiberoptic phototherapy blankets (biliblankets) wrapped directly around the infant's torso inside the transport isolette. When combined with overhead LED phototherapy units, maximum body surface area is irradiated with blue-green light (wavelength 460 to 490 nm), converting toxic (4Z,15Z)-bilirubin into water-soluble photoisomers (lumirubin) excreted in bile and urine without hepatic conjugation.
Eye Protection: Opaque eye shields (goggles) must be securely applied over the infant's closed eyes to shield retina from irreversible photochemical toxicity. Transport Safety Check: Frequently verify that the eye patch has not slipped down to occlude the neonate's nares or mouth during transport vibration.
Hydration & Thermal Monitoring: Phototherapy increases insensible fluid losses by 20% to 40% and can induce thermal instability. Maintain rigorous temperature monitoring and titrate intravenous hydration.
Preparation for Double-Volume Exchange Transfusion (DVET)
When total serum bilirubin reaches the exchange-transfusion threshold in the 2022 AAP clinical practice guideline (hour-specific thresholds that depend on gestational age and neurotoxicity risk factors), or whenever an infant shows signs of intermediate or advanced ABE, emergency double-volume exchange transfusion is indicated. The 2022 guideline also defines an escalation-of-care threshold 2 mg/dL below the exchange level, at which intensive phototherapy, urgent labs, and transfer to a center that can perform an exchange begin. In isoimmune hemolytic disease with bilirubin rising despite intensive phototherapy, IVIG (0.5–1 g/kg) may be given.
Exchange Volume Calculation: Neonatal circulating blood volume is 80 to 90 mL/kg for term infants ( 90 – 100 mL/kg 90\text{--}100 \text{ mL/kg} 90 – 100 mL/kg for preterms). Double-Volume Exchange Transfusion Volume = 2 × Blood Volume = 160 to 180 mL/kg \text{Double-Volume Exchange Transfusion Volume} = 2 \times \text{Blood Volume} = 160 \text{ to } 180 \text{ mL/kg} Double-Volume Exchange Transfusion Volume = 2 × Blood Volume = 160 to 180 mL/kg
Blood Product Selection: Reconstituted whole blood with a hematocrit of 45% to 50%, composed of type O-negative (or Rh-compatible) packed red blood cells crossmatched against maternal serum, suspended in AB plasma (fresh frozen plasma).
Transport Team Preparation: Prior to transport departure, insert both an Umbilical Venous Catheter (UVC) and Umbilical Arterial Catheter (UAC) . This dual-line setup allows continuous isovolumetric exchange (simultaneously withdrawing blood through the UAC while infusing reconstituted blood through the UVC), eliminating dangerous intracranial and systemic blood pressure spikes associated with older single-line push-pull techniques.